Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
AAPL$352.96+21.32(+6.43%)Apple's Pain Could Be Micron's Gain as Memory Prices Surge12:33:14 PM ETAAPL$352.96+21.32(+6.43%)Apple Rallies as Big Tech Comes Back: What It Means for Your Index Fund12:33:00 PM ETXOM$168.14-9.36(-5.27%)Will ExxonMobil's 100,000-BPD Diesel Expansion Boost Refining Profit?12:31:08 PM ETCRWD$242.64-2.00(-0.82%)CrowdStrike Launches Sovereign Cloud in Saudi Arabia, Bringing AI-Native Cybersecurity to the Kingdom12:28:00 PM ETSPCX$137.64-3.69(-2.61%)SPCX Cloud Growth Reshapes the Earnings Story After a Blowout Q3 Beat12:20:58 PM ETSPCX$137.64-3.69(-2.61%)Is SPCX Worth Buying as Growth Surges but Valuation Stays Stretched?12:20:55 PM ETANET$178.06+8.09(+4.76%)ANET Q3 Earnings Beat Estimates on Strong AI and Enterprise Demand12:20:53 PM ETSPCX$137.64-3.69(-2.61%)SPCX Sinks 17.8% in a Month as Growth Meets Rising Spending Risks12:20:52 PM ETAAPL$352.96+21.32(+6.43%)Apple stock hit a new all-time high on Wednesday: what's fuelling the rally?12:18:17 PM ETAMZN$269.48+18.70(+7.46%)Amazon Surges After Democrats Take Congress. Here's Which ETFs Feel It Most12:06:31 PM ETSPCX$137.64-3.69(-2.61%)SpaceX: Super Intelligence Segment Turns It Into An AI Infrastructure Heavyweight12:05:26 PM ETNFLX$66.06+2.69(+4.24%)Netflix Is Playing a Bigger Game. Investors Should Take Notice12:03:26 PM ETACN$263.52+8.96(+3.52%)Accenture vs. Oracle: Which Technology Stock Is a Better Buy in 2027?12:00:02 PM ETBRK-A$859,873.63+23,743.34(+2.84%)Berkshire Hathaway Buys More Sirius XM, Sending Stock to 52-Week High11:56:00 AM ETNVDA$203.29-3.27(-1.58%)Can NVDA Stock Jump From Here?11:55:23 AM ETPLTR$170.40-4.94(-2.82%)Why Palantir Technologies Stock Dropped Today11:46:23 AM ETTSLA$389.78-8.56(-2.15%)Tesla's Five Year Stock Price Turns Negative11:46:03 AM ETSHOP$151.76+9.05(+6.34%)Cathie Wood Bought $12.5 Million of Shopify as It Tanked11:37:31 AM ETTSLA$389.78-8.56(-2.15%)Musk's Election Bet Backfires on Tesla, and Your Index Fund Owns a Piece of It11:33:41 AM ETINTC$59.18-1.32(-2.18%)Intel Just Delivered Its Strongest Data Center Growth in 15 Years. Its Comeback Is Gaining Momentum11:33:28 AM ETAMD$487.20+3.37(+0.70%)AMD Rallies After Chipmaker "Beat Where It Mattered" in Earnings11:30:19 AM ETWMT$130.38+5.54(+4.44%)Walmart's Dec. 11 Dividend Isn't the Real Reason to Own the Stock11:30:00 AM ETCEG$247.34-15.96(-6.06%)Constellation Energy Earnings Preview: Why I Remain Bullish Headed Into Q311:21:39 AM ETMU$810.16-44.77(-5.24%)Micron, SK Hynix, SanDisk stocks fall: why Dems' Texas win is spooking investors11:19:40 AM ET

AQST · NASDAQ

Aquestive Therapeutics, Inc.

$4.01 +0.14 (+3.62%)

Company overview

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of Lennox-Gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Market cap
$503M
Employees
142
Headquarters
Warren, NJ
Website
aquestive.com
CEO
Daniel Barber
Listed
July 25, 2018
P/E
-6.56
Dividend yield
0.00%

Company financials

Revenue
$50.3M
Gross profit
$31.9M
Operating income
-$55.9M
EBITDA
-$55.4M
Net income
-$68.9M
EPS
-$0.61
Total assets
$141M
Total debt
$134M
Gross margin
63.45%
Net margin
-137.08%
Earnings yield
-15.25%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

3.484.004.525.045.56
AQST 1D NASDAQ O3.78H3.94L3.78C3.87+0.10 (+2.65%)Vol1.69M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
AQSTAquestive Therapeutics, Inc. Stock news What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call MarketBeat
AQSTAquestive Therapeutics, Inc. Stock news Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates Zacks Investment Research
AQSTAquestive Therapeutics, Inc. Press release Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
AQSTAquestive Therapeutics, Inc. Legal Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Shareholders to Inquire about Securities Investigation ACCESS Newswire
AQSTAquestive Therapeutics, Inc. Stock news 4 Biotech Stocks Seeing Unusual Options Volume Today Schaeffers Research
AQSTAquestive Therapeutics, Inc. Legal Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect ACCESS Newswire
AQSTAquestive Therapeutics, Inc. Press release Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET GlobeNewswire
AQSTAquestive Therapeutics, Inc. Stock news Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $105,500.00 in Stock Defense World
AQSTAquestive Therapeutics, Inc. Stock news Aquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating Upgrade Seeking Alpha
AQSTAquestive Therapeutics, Inc. Legal Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation ACCESS Newswire
AQSTAquestive Therapeutics, Inc. Press release Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 GlobeNewswire
AQSTAquestive Therapeutics, Inc. Press release Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film GlobeNewswire
AQSTAquestive Therapeutics, Inc. Legal Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop PRNewsWire
AQSTAquestive Therapeutics, Inc. Press release Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly GlobeNewswire
AQSTAquestive Therapeutics, Inc. Press release Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film GlobeNewswire
AQSTAquestive Therapeutics, Inc. Press release Aquestive Therapeutics to Participate in Upcoming September Investor Conferences GlobeNewswire
AQSTAquestive Therapeutics, Inc. Stock news Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript Seeking Alpha
AQSTAquestive Therapeutics, Inc. Stock news Aquestive Therapeutics Q2 Earnings Call Highlights MarketBeat
AQSTAquestive Therapeutics, Inc. Stock news Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates Zacks Investment Research
AQSTAquestive Therapeutics, Inc. Press release Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
See more
FAQ

Questions about Aquestive Therapeutics, Inc.

What does Aquestive Therapeutics, Inc. do?
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of Lennox-Gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
What is AQST's market cap?
Aquestive Therapeutics, Inc. (AQST) is a listed stock with a live quote. The latest market cap on this page is $503M.
Where is Aquestive Therapeutics, Inc. headquartered?
Aquestive Therapeutics, Inc. is headquartered in Warren, NJ.
How do I get AQST news from the API?
Call GET /v1/news?tickers=AQST. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does AQST news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for AQST, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the AQST price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs